Comprehensive Analysis of Expression, Prognosis and Immune Infiltration for TIMPs in Glioblastoma

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2021 Nov 16

PMID 34781885

Citations 10

Authors

Jinkun Han

Yajun Jing

Fubing Han

Peng Sun

Affiliations

Soon will be listed here.

Abstract

Background: Tissue inhibitors of metalloproteinase (TIMP) family proteins are peptidases involved in extracellular matrix (ECM) degradation. Various diseases are related to TIMPs, and the primary reason is that TIMPs can indirectly regulate remodelling of the ECM and cell signalling by regulating matrix metalloproteinase (MMP) activity. However, the link between TIMPs and glioblastoma (GBM) is unclear.

Objective: This study aimed to explore the role of TIMP expression and immune infiltration in GBM.

Methods: Oncomine, GEPIA, OSgbm, LinkedOmics, STRING, GeneMANIA, Enrichr, and TIMER were used to conduct differential expression, prognosis, and immune infiltration analyses of TIMPs in GBM.

Results: All members of the TIMP family had significantly higher expression levels in GBM. High TIMP3 expression correlated with better overall survival (OS) and disease-specific survival (DSS) in GBM patients. TIMP4 was associated with a long OS in GBM patients. We found a positive relationship between TIMP3 and TIMP4, identifying gene sets with similar or opposite expression directions to those in GBM patients. TIMPs and associated genes are mainly associated with extracellular matrix organization and involve proteoglycan pathways in cancer. The expression levels of TIMPs in GBM correlate with the infiltration of various immune cells, including CD4+ T cells, macrophages, neutrophils, B cells, CD8 T cells, and dendritic cells.

Conclusions: Our study inspires new ideas for the role of TIMPs in GBM and provides new directions for multiple treatment modalities, including immunotherapy, in GBM.

Citing Articles

TIMP4 serves as a novel potential prognostic biomarker for oral squamous cell carcinoma.

Zhou L, Tang C, Shuai R, Chen B, Yang X, He Y Sci Rep. 2025; 15(1):6313.

PMID: 39984587 PMC: 11845745. DOI: 10.1038/s41598-025-90237-3.

Unlocking the Potential of Circulating miRNAs as Biomarkers in Glioblastoma.

Suvarnapathaki S, Serrano-Farias A, Dudley J, Bettegowda C, Rincon-Torroella J Life (Basel). 2024; 14(10).

PMID: 39459612 PMC: 11509808. DOI: 10.3390/life14101312.

Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance.

Tataranu L, Turliuc S, Kamel A, Rizea R, Dricu A, Staicu G Curr Issues Mol Biol. 2024; 46(9):9881-9894.

PMID: 39329940 PMC: 11430601. DOI: 10.3390/cimb46090588.

Acquired Temozolomide Resistance Instructs Patterns of Glioblastoma Behavior in Gelatin Hydrogels.

Kriuchkovskaia V, Eames E, Riggins R, Harley B Adv Healthc Mater. 2024; 13(27):e2400779.

PMID: 39030879 PMC: 11518645. DOI: 10.1002/adhm.202400779.

Extracellular Matrix Structure and Interaction with Immune Cells in Adult Astrocytic Tumors.

Di Vito A, Donato A, Bria J, Conforti F, La Torre D, Malara N Cell Mol Neurobiol. 2024; 44(1):54.

PMID: 38969910 PMC: 11226480. DOI: 10.1007/s10571-024-01488-z.

References

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Mashayekhi F, Saberi A, Mashayekhi S . Serum TIMP1 and TIMP2 concentration in patients with different grades of meningioma. Clin Neurol Neurosurg. 2018; 170:84-87. DOI: 10.1016/j.clineuro.2018.05.001. View

Kenig S, Duran Alonso M, Mueller M, Lah T . Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett. 2009; 289(1):53-61. DOI: 10.1016/j.canlet.2009.07.014. View

Bowman R, Wang Q, Carro A, Verhaak R, Squatrito M . GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 2016; 19(1):139-141. PMC: 5193031. DOI: 10.1093/neuonc/now247. View

Ostrom Q, Bauchet L, Davis F, Deltour I, Fisher J, Langer C . The epidemiology of glioma in adults: a "state of the science" review. Neuro Oncol. 2014; 16(7):896-913. PMC: 4057143. DOI: 10.1093/neuonc/nou087. View

Wang J, Li X, Gao X, An S, Liu H, Liang J . Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2013; 17(4):427-35. View

Span P, Lindberg R, Manders P, Tjan-Heijnen V, Heuvel J, Beex L . Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. J Pathol. 2004; 202(4):395-402. DOI: 10.1002/path.1528. View

Melendez-Zajgla J, Del Pozo L, Ceballos G, Maldonado V . Tissue inhibitor of metalloproteinases-4. The road less traveled. Mol Cancer. 2008; 7:85. PMC: 2599898. DOI: 10.1186/1476-4598-7-85. View

Bockelman C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, Tervahartiala T, Mustonen H . Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. BMC Cancer. 2018; 18(1):679. PMC: 6013876. DOI: 10.1186/s12885-018-4589-x. View

10.

Bredel M, Bredel C, Juric D, Harsh G, Vogel H, Recht L . Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res. 2005; 65(19):8679-89. DOI: 10.1158/0008-5472.CAN-05-1204. View

11.

Li T, Fan J, Wang B, Traugh N, Chen Q, Liu J . TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017; 77(21):e108-e110. PMC: 6042652. DOI: 10.1158/0008-5472.CAN-17-0307. View

12.

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

13.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin N . Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. DOI: 10.1016/j.ccr.2006.03.030. View

14.

Chen E, Tan C, Kou Y, Duan Q, Wang Z, Meirelles G . Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013; 14:128. PMC: 3637064. DOI: 10.1186/1471-2105-14-128. View

15.

Miyake M, Furuya H, Onishi S, Hokutan K, Anai S, Chan O . Monoclonal Antibody against CXCL1 (HL2401) as a Novel Agent in Suppressing IL6 Expression and Tumoral Growth. Theranostics. 2019; 9(3):853-867. PMC: 6376461. DOI: 10.7150/thno.29553. View

16.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

17.

Fassina G, Ferrari N, Brigati C, Benelli R, Santi L, Noonan D . Tissue inhibitors of metalloproteases: regulation and biological activities. Clin Exp Metastasis. 2001; 18(2):111-20. DOI: 10.1023/a:1006797522521. View

18.

Gu B, Li M, Zhang Y, Li L, Yao K, Wang S . DR7 encoded by human herpesvirus 6 promotes glioma development and progression. Cancer Manag Res. 2019; 11:2109-2118. PMC: 6419595. DOI: 10.2147/CMAR.S179762. View

19.

Arpino V, Brock M, Gill S . The role of TIMPs in regulation of extracellular matrix proteolysis. Matrix Biol. 2015; 44-46:247-54. DOI: 10.1016/j.matbio.2015.03.005. View

20.

Kristensen B, Priesterbach-Ackley L, Petersen J, Wesseling P . Molecular pathology of tumors of the central nervous system. Ann Oncol. 2019; 30(8):1265-1278. PMC: 6683853. DOI: 10.1093/annonc/mdz164. View